BRIEF-Phio Pharmaceuticals Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762

Reuters

19 Dec 2024

BRIEF-<a href="https://laohu8.com/S/PHIO">Phio Pharmaceuticals</a> Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762

Dec 19 (Reuters) - Phio Pharmaceuticals Corp PHIO.O:

PHIO PHARMACEUTICALS: POSITIVE SAFETY MONITORING COMMITTEE RECOMMENDATION TO CONTINUE TO THIRD DOSE COHORT IN ITS CLINICAL STUDY OF PH-762
INTRATUMORAL INJECTIONS HAVE BEEN WELL TOLERATED
NO DOSE-LIMITING TOXICITIES, OR SERIOUS ADVERSE EVENTS IN PARTICIPANTS RECEIVING INTRATUMORAL PH-762

Source text: [ID:n0001683168-24-008833]

Further company coverage: PHIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2492176572"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492176572\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492176572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492176572","market":"us","top_or_hot":-1,"title":"BRIEF-Phio Pharmaceuticals Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PHIO\">Phio Pharmaceuticals</a> Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762</title></head><body><p><span>Dec 19 (Reuters)</span><span> - </span>Phio Pharmaceuticals Corp <span>PHIO.O</span>:</p><ul><li><p>PHIO PHARMACEUTICALS: POSITIVE SAFETY MONITORING COMMITTEE RECOMMENDATION TO CONTINUE TO THIRD DOSE <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> IN ITS CLINICAL STUDY OF PH-762</p></li><li><p>INTRATUMORAL INJECTIONS HAVE BEEN WELL TOLERATED</p></li><li><p>NO DOSE-LIMITING TOXICITIES, OR SERIOUS ADVERSE EVENTS IN PARTICIPANTS RECEIVING INTRATUMORAL PH-762</p></li></ul><p>Source text: [ID:n0001683168-24-008833]</p><p>Further company coverage: <span>PHIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Phio Pharmaceuticals Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Phio Pharmaceuticals Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-19 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PHIO\">Phio Pharmaceuticals</a> Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762</title></head><body><p><span>Dec 19 (Reuters)</span><span> - </span>Phio Pharmaceuticals Corp <span>PHIO.O</span>:</p><ul><li><p>PHIO PHARMACEUTICALS: POSITIVE SAFETY MONITORING COMMITTEE RECOMMENDATION TO CONTINUE TO THIRD DOSE <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> IN ITS CLINICAL STUDY OF PH-762</p></li><li><p>INTRATUMORAL INJECTIONS HAVE BEEN WELL TOLERATED</p></li><li><p>NO DOSE-LIMITING TOXICITIES, OR SERIOUS ADVERSE EVENTS IN PARTICIPANTS RECEIVING INTRATUMORAL PH-762</p></li></ul><p>Source text: [ID:n0001683168-24-008833]</p><p>Further company coverage: <span>PHIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK0HN:1","article_id":"2492176572","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492176572","pubTimestamp":1734617721,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Phio Pharmaceuticals Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762Dec 19  - Phio Pharmaceuticals Corp PHIO.O:PHIO PHARMACEUTICALS: POSITIVE SAFETY MONITORING COMMITTEE RECOMMENDATION TO CONTINUE TO THIRD DOSE COHORT IN ITS CLINICAL STUDY OF PH-762INTRATUMORAL INJECTIONS HAVE BEEN WELL TOLERATEDNO DOSE-LIMITING TOXICITIES, OR SERIOUS ADVERSE EVENTS IN PARTICIPANTS RECEIVING INTRATUMORAL PH-762Source text: [ID:n0001683168-24-008833]Further company coverage: PHIO.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PHIO":"Phio Pharmaceuticals"},"translate_title":"BRIEF-Phio Pharmaceuticals积极安全监测委员会建议继续进行Ph-762临床研究的第三剂队列","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHIO":0.9},"content_text":"BRIEF-Phio Pharmaceuticals Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762Dec 19 (Reuters) - Phio Pharmaceuticals Corp PHIO.O:PHIO PHARMACEUTICALS: POSITIVE SAFETY MONITORING COMMITTEE RECOMMENDATION TO CONTINUE TO THIRD DOSE COHORT IN ITS CLINICAL STUDY OF PH-762INTRATUMORAL INJECTIONS HAVE BEEN WELL TOLERATEDNO DOSE-LIMITING TOXICITIES, OR SERIOUS ADVERSE EVENTS IN PARTICIPANTS RECEIVING INTRATUMORAL PH-762Source text: [ID:n0001683168-24-008833]Further company coverage: PHIO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}